证券代码：300430 证券简称：诚益通 公告编号：2025-045 北京诚益通控制技术集团股份有限公司 关于为上市公司及子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、融资情况概述 北京诚益通控制技术集团股份有限公司（以下简称"公司"或"诚益通"） 于 2025 年 4 月 23 日召开了第五届董事会第十一次会议，会议审议通过了《关于 预计 2025 年度公司及合并范围内公司申请银行综合授信及项目贷款额度的议案》 《关于预计 2025 年度公司及合并范围内公司担保额度的议案》（公告编号： 2025-020、021），同意公司、子公司及合并报表范围内的子公司、孙公司向银 行及其他金融机构申请合计额度不超过人民币 13.79 亿元的授信等业务，在授权 期限内额度可循环使用，担保总额合计不超过 13.19 亿元。上述议案同时由 2025 年 5 月 15 日召开的 2024 年度股东大会审议通过。 二、融资进展情况 近期，北京诚益通博日鸿智能装备技术有限公司（以下简称"博日鸿"）、 北京诚益通科技有限公司（以下简称"诚益通科技"）、北 ...

Core Insights - The Ministry of Industry and Information Technology is promoting the establishment of digital transformation centers for manufacturing across 14 key industries, including petrochemicals, machinery, aviation, shipping, automotive, pharmaceuticals, and electronic information [1] Group 1: Digital Transformation Centers - A total of 62 manufacturing digital transformation centers have been proposed for establishment, with 7 units from Beijing leading the nation in numbers [1] - The selected units include Beijing Chengyitong Control Technology Group Co., Ltd., Beizhi Institute, National Industrial Information Security Development Research Center, Holley Technology, Gonglian Institute, China Academy of Information and Communications Technology, and AVIC International Golden Network [1] - Beijing Chengyitong and AVIC International Golden Network are established as independent entities, while the others are leading joint ventures [1] Group 2: Next Steps - The Beijing Economic and Information Technology Bureau will intensify guidance for the construction entities, enhance cooperation, and leverage the centers' roles in project implementation, supply-demand matching, and data sharing [1] - The aim is to accelerate the large-scale, in-depth, and high-level promotion of digital transformation in the manufacturing sector [1]

Group 1 - The company Cheng Yitong announced that its controlling shareholder, Li Weite, has completed a partial equity pledge transaction [2] - The pledged amount is 1.9 million shares, which represents 3.71% of the shares held by Li Weite and 0.70% of the company's total share capital [2] - The pledge is made to Beijing Daxing Development Rongda Financing Guarantee Co., Ltd., and the purpose of the pledge is to replace a previous pledge [2]

证券代码：300430 证券简称：诚益通 公告编号：2025-043 北京诚益通控制技术集团股份有限公司 关于控股股东部分股权质押的公告 公司控股股东保证向公司提供的信息内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。本公司及董事会全体成员保证信息披露的内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 北京诚益通控制技术集团股份有限公司（以下简称"公司"或"本公司"） 近日接到公司控股股东北京立威特投资有限责任公司（以下简称"立威特"）的 通知，获悉其持有的本公司股份办理了部分股权质押业务，具体事项如下： 一、股份质押的基本情况 | 股东 | 是否为控 股股东或 | 本次质 | 占其所 | 占公司 | 是否为 | 是否为 | 质押起 | 质押到 | | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 第一大股 | 押数量 | 持股份 | 总股本 | 限售股 | 补充质 | 始日 | 期日 | 质权人 | 用途 | | | 东及其一 | （万股） | 比例 | 比例 | | 押 ...

9月2日，诚益通跌5.04%，截至发稿，报21.68元/股，成交2.57亿元，换手率4.47%，总市值59.20亿元。 责任编辑：小浪快报 资料显示，北京诚益通控制技术集团股份有限公司位于北京市大兴区生物医药产业基地庆丰西路27号， 成立日期2003年7月22日，上市日期2015年3月19日，公司主营业务涉及提供医药、生物工业自动化控制 系统整体解决方案;康复理疗医疗器械的研发、生产和销售业务。主营业务收入构成为：智能制造业务 71.11%，康复医疗业务28.89%。 从基金十大重仓股角度 数据显示，北信瑞丰基金旗下1只基金重仓诚益通。北信瑞丰健康生活主题灵活配置（001056）二季度 减持4万股，持有股数20万股，占基金净值比例为4.67%，位居第八大重仓股。根据测算，今日浮亏损 失约23万元。 北信瑞丰健康生活主题灵活配置（001056）成立日期2015年3月27日，最新规模8937.79万。今年以来收 益38.34%，同类排名1631/8184；近一年收益69.28%，同类排名1290/7971；成立以来收益31.7%。 北信瑞丰健康生活主题灵活配置（001056）基金经理为庞文杰。 截至发稿，庞文杰累 ...

证券代码：300430 证券简称：诚益通 公告编号：2025-042 北京诚益通控制技术集团股份有限公司 关于使用闲置自有资金进行委托理财的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京诚益通控制技术集团股份有限公司（以下简称"公司"）于 2025 年 5 月 14 日召开 2024 年度股东大会，审议通过了《关于使用闲置自有资金进行委托 理财的议案》。同意公司及子公司使用额度不超过 1 亿元人民币的闲置自有资金 进行委托理财，购买低风险、流动性好、安全性高的理财产品，上述额度可由公 司及子公司共同滚动使用，并授权公司管理层具体实施相关事宜，期限自 2024 年度股东大会审议通过之日起至 2025 年度股东大会召开之日止，同意对相关理 财的资金情况每月定期披露进展。 近日公司及子公司使用闲置自有资金在授权范围内购买了理财产品，现将相 关事项公告如下： | 投资主体 | 受托方 | 关联 | 产品名称 | 产品 | 委托理财金 | 起息日 | 到期日 | 预期年 化收益 | | --- | --- | --- | --- | --- | --- ...

Core Viewpoint - The recent financial report of Cheng Yi Tong (300430) indicates a significant decline in revenue and net profit for the first half of 2025 compared to the previous year, raising concerns about the company's financial health and operational efficiency [1] Financial Performance - Total revenue for the first half of 2025 was 408 million yuan, a decrease of 36.65% year-on-year [1] - Net profit attributable to shareholders was 51.18 million yuan, down 38.76% year-on-year [1] - In Q2 2025, total revenue was 219 million yuan, reflecting a 41.81% decline year-on-year, while net profit was 38.59 million yuan, a decrease of 26.9% [1] - The gross margin was 38.64%, down 2.2% year-on-year, and the net margin was 10.76%, down 17.02% year-on-year [1] - The total of financial, sales, and administrative expenses reached 89.18 million yuan, accounting for 21.86% of total revenue, an increase of 57.09% year-on-year [1] Cash Flow and Assets - Cash and cash equivalents increased to 264 million yuan, a rise of 38.35% year-on-year [1] - Accounts receivable decreased to 774 million yuan, down 26.85% year-on-year [1] - Interest-bearing debt slightly decreased to 630 million yuan, down 2.74% year-on-year [1] Investment Returns - The company's Return on Invested Capital (ROIC) was 3.84% last year, indicating weak capital returns [3] - The historical median ROIC since the company went public is 7.31%, suggesting average investment returns [3] - The net profit margin last year was 9.21%, indicating that the added value of products or services is generally low [3] Market Position and Analyst Expectations - Analysts expect the company's performance in 2025 to reach 99 million yuan, with an average earnings per share of 0.36 yuan [3] - The company relies heavily on research and marketing for its performance, necessitating a deeper analysis of these driving factors [3] Fund Holdings - The largest fund holding Cheng Yi Tong is the Huaxia Leading Stock Fund, which has increased its position to 1.4626 million shares [4] - The fund's current scale is 704 million yuan, with a recent net value of 0.591, down 1.99% from the previous trading day, but up 38.73% over the past year [4]

Core Viewpoint - The company has established a dual-track strategy focusing on both invasive and non-invasive medical applications, particularly in the field of brain-computer interfaces (BCIs) [1] Group 1: Non-Invasive Medical Applications - The company is currently integrating existing rehabilitation devices with brain-computer interfaces to enhance product functionality and is actively promoting commercialization [1] - In addition to the medical field, the company is exploring non-medical applications in various sectors, including education, elderly care, and health [1] - In the education sector, the company has launched a brain-computer interface biofeedback system aimed at attention detection and training [1] Group 2: Invasive Medical Applications - The company is constructing a research verification center and an animal testing center for its brain-computer interface technology, which are crucial for its strategic layout in this field [1] - These two centers will create a complete innovation chain from basic research to technology verification and result transformation [1]

Core Insights - The company reported a significant decline in revenue and net profit for the first half of 2025, with total revenue of 408 million yuan, representing a year-on-year decrease of 36.65% [1] - The net profit attributable to shareholders was 51 million yuan, down 38.76% compared to the previous year [1] Revenue Breakdown - Revenue from control systems was 223 million yuan, showing a year-on-year decline of 46.12% [1] - Revenue from rehabilitation medical devices reached 118 million yuan, down 18.10% year-on-year [1] - Revenue from system equipment and other segments was 67 million yuan, reflecting a year-on-year decrease of 19.50% [1] Market Positioning - The company is leveraging its "Longzhijie" brand to enter the blue ocean market of rehabilitation medicine [1] - "Longzhijie" has a comprehensive product line in physical factor therapy products, including electrotherapy, phototherapy, magnetotherapy, pressure therapy, and exercise therapy [1]

公募基金方面，本期较上一期持股增加的公募基金共计1个，即华夏领先股票，持股增加占比小幅上 涨。本期较上一季度持股减少的公募基金共计1个，即北信瑞丰健康生活主题灵活配置，持股减少占比 小幅下跌。本期较上一季度新披露的公募基金共计2个，包括银河康乐股票A、大成智惠量化多策略混 合A。本期较上一季未再披露的公募基金共计2个，包括广发聚丰混合A、诺安优势行业混合A。 2025年8月27日，诚益通(300430.SZ)发布2025年半年度报告。截至2025年8月26日，共有6个机构投资者 披露持有诚益通A股股份，合计持股量达5332.57万股，占诚益通总股本的19.53%。其中，机构投资者 包括北京立威特投资有限责任公司、中国工商银行股份有限公司-华夏领先股票型证券投资基金、银河 康乐股票A、北信瑞丰健康生活主题灵活配置、富荣福银混合A、大成智惠量化多策略混合A，机构投 资者合计持股比例达19.53%。相较于上一季度，机构持股比例合计下跌了0.74个百分点。 ...